Jobs / United States / Pfizer INC
Postdoctoral Research Fellow – Endogenous Biomarkers and Translational ADME
Pfizer INC · 🇺🇸 United States - Connecticut - Groton
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 40 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 9 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Pfizer INC paid sponsored hires in similar roles2 certified filings for “Postdoctoral Fellow, Biophysics Small Molecule Discovery” (Biochemists and Biophysicists) in CA: $90k–$135k, median $113k. Most were filed at wage level I (50%) — 1 lottery entry, ≈15% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Pfizer INC
The US Department of Labor certified 40 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 9 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Pfizer INC →
About the role
Goal We are seeking a highly motivated Postdoctoral Fellow to advance the discovery, mechanistic qualification, and clinical translation of endogenous biomarkers of cytochrome P450 (CYP) enzyme activities. Reliable assessment of CYP inhibition and induction is important for predicting clinical drug-drug interactions, but available endogenous biomarkers remain limited by biological variability, insufficient sensitivity, and incomplete mechanistic understanding. The successful candidate will lead experimental and analytical research toward establishing a mechanistically qualified biomarker panel by integrating clinical biomarker analysis, multiplex LC-MS/MS bioanalysis, mechanistic ADME studies, pharmacokinetic data analysis, and physiologically based pharmacokinetic modeling. What You Will Achieve In this role, you will: • Evaluate candidate biomarkers across diverse clinical datasets and investigate biological and mechanistic factors that influence their performance. • Determine how metabolic enzymes, membrane transporters, renal and biliary clearance, and enterohepatic processes influence biomarker disposition. • Identify and mechanistically explain variability or discordance among candidate biomarkers. • Develop a quantitative relationship between endogenous biomarker responses and changes in the pharmacokinetics of sensitive CYP substrates. • Advance the scientific foundation for incorporating endogenous biomarkers into clinical DDI assessment and drug-development decision-making. • Develop expertise across bioanalysis, mechanistic ADME, clinical pharmacology, quantitative modeling, and scientific communication. Here Is What You Need (Minimum Requirements): • PhD in pharmaceutical sciences, pharmacology, pharmacokinetics, drug metabolism, analytical chemistry, biochemistry, biomedical sciences, chemical biology, quantitative pharmacology, or a closely related discipline. • Strong scientific training in at least one area directly relevant to the project, such as bioanalysis, metabolomics, drug metabolism, mechanistic ADME, enzymology, membrane transporter science, pharmacokinetics, or quantitative pharmacology, with demonstrated ability or interest in working across multiple scientific disciplines. • Relevant hands-on research experience in bioanalysis, in vitro drug metabolism, membrane transporter research, or another experimental area directly related to mechanistic ADME. • Demonstrated experience designing, conducting, analyzing, and interpreting hypothesis-driven research. • Ability to critically analyze complex experimental or quantitative datasets and draw scientifically supported conclusions. • Evidence of scientific productivity through peer-reviewed publications, submitted manuscripts, conference presentations, or comparable research contributions. • Strong written and verbal communication skills, including the ability to present research findings clearly and contribute to scientific manuscripts. • Ability to work effectively and collaboratively in a multidisciplinary research environment. • Strong organizational skills, attention to experimental detail, and the ability to manage multiple research activities. Bonus Points If You Have (Preferred Requirements): • Strong hands-on experience with quantitative LC-MS/MS, including assay development, optimization, and analysis of small molecules, metabolites, or endogenous biomarkers in biological matrices. • Hands-on experience with in vitro ADME assays, with preference for experience using recombinant CYP enzymes, human liver microsomes, or hepatocytes; relevant transporter-assay experience is also highly valued. • Strong knowledge of pharmacokinetic and drug-drug interaction principles, including clearance, exposure, concentration-time relationshi